hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06270446 id: DSRB 2019/01135 briefTitle: Community Based Rehabilitation Model After Total Knee Replacement overallStatus: COMPLETED date: 2021-01-01 date: 2022-07-01 date: 2022-07-01 date: 2024-02-21 date: 2024-02-21 name: Tan Tock Seng Hospital class: OTHER briefSummary: To investigate the clinical efficacy of community-based early stage knee replacement rehabilitation program as compared with usual care in acute hospital outpatient clinic conditions: Knee Osteoarthritis studyType: INTERVENTIONAL phases: NA allocation: NON_RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE maskingDescription: Data analysis blinded count: 59 type: ACTUAL name: Community based physiotherapy name: Outpatient physiotherapy measure: TUG measure: 30 sec chair stand test measure: Pain intensity measure: Knee flexion and extension measure: Passive range of motion measure: Presence of lag measure: OKS sex: ALL minimumAge: 55 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Tan Tock Seng Hospital city: Singapore country: Singapore lat: 1.28967 lon: 103.85007 hasResults: False
nctId: NCT06270433 id: 2023-KY142-01 briefTitle: Efficacy and Safety of Toludesvenlafaxine Hydrochloride Sustained-release Tablets Versus Desvenlafaxine Succinate Sustained-release Tablets Targeting Anhedonia in Patients With Major Depression Disorder overallStatus: RECRUITING date: 2024-02-19 date: 2024-12-31 date: 2024-12-31 date: 2024-02-21 date: 2024-04-29 name: Jiangsu Province Nanjing Brain Hospital class: OTHER briefSummary: The purpose of this study is to evaluate efficacy and safety of toludesvenlafaxine hydrochloride sustained-release tablets in the treatment of anhedonia in patients with major depression disorder compared to desvenlafaxine succinate sustained-release tablets, to provide evidence-based basis for clinical rational drug use. conditions: Anhedonia studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 80 type: ESTIMATED name: Toludesvenlafaxine hydrochloride sustained-release tablets name: Desvenlafaxine succinate sustained-release tablets measure: Snaith-Hamilton Pleasure Scale (SHAPS) Total Score measure: Snaith-Hamilton Pleasure Scale (SHAPS) Total Score measure: Snaith-Hamilton Pleasure Scale (SHAPS) Reductive Rate measure: Dimensional Anhedonia Rating Scale (DARS) Score measure: Montgomery-Asberg Depression Rating Scale (MADRS) Score measure: 17-item Hamilton Depression Rating Scale (HAM-D17) Score measure: Sheehan Disability Scale (SDS) Score measure: Quality of Life Enjoyment and Satisfaction Questionnaire Short Form (Q-LES-Q-SF) Score measure: Rating Scale for Side Effects (SERS) Score measure: Arizona Sexual Experience Scale (ASEX) Score measure: Count of red blood cell in blood measure: Count of white blood cell in blood measure: Count of platelet in blood measure: Concentration of hemoglobin in blood measure: Concentration of alanine aminotransferase in blood measure: Concentration of aspartate aminotransferase in blood measure: Concentration of gamma-glutamyltransferase in blood measure: Concentration of blood glucose in blood measure: Concentration of serum creatinine in blood measure: Concentration of urea in blood measure: Concentration of total cholesterol in blood measure: Concentration of high density lipoprotein in blood measure: Concentration of low density lipoprotein in blood measure: Concentration of triglyceride in blood measure: Concentration of thyroid-stimulating hormone in blood measure: Concentration of protein in urine measure: Concentration of sugar in urine measure: Count of white blood cell in urine measure: Count of red blood cell in urine measure: ECG QT Interval measure: Changes in weight measure: Changes in pulse measure: Changes in both systolic and diastolic blood pressure measure: Changes in respiration rate measure: Changes in armpit temperature sex: ALL minimumAge: 18 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Nanjing Brian Hospital status: RECRUITING city: Nanjing state: Jiangsu zip: 210024 country: China name: Hao Tang, MD role: CONTACT phone: +8618913821366 email: tanghao997@163.com lat: 32.06167 lon: 118.77778 hasResults: False
nctId: NCT06270420 id: 2022.04 briefTitle: Technological Devices and Home Automation System in Neurological Rehabilitation acronym: SMART overallStatus: RECRUITING date: 2023-02-05 date: 2024-03-31 date: 2024-05-30 date: 2024-02-21 date: 2024-02-21 name: IRCCS San Camillo, Venezia, Italy class: OTHER briefSummary: The use of home automation system may be useful in rehabilitation to collect data about the environment and the amount of therapy. Then, the data may be stored in a cloud and integrated with data collected during training provided by technological devices.
The main goal of this longitudinal pilot study is to define the productivity of the rehabilitation room (i.e., HoSmartAI room) in the IRCCS San Camillo Hospital (Venice, Italy) service, where the investigators will install home automation sensors and treat patients with neurological disease using technological devices (e.g., robotic and virtual reality). The secondary goals are to define the patients' satisfaction, usability of the system and the clinical effect of treatments delivered with technological devices in the HoSmartAI room. The patient will be assessed to personalized the treatment based on their needs. The treatment will consist of 15 sessions (1h/day, 5day/week, 3 weeks). At the end of the study, the patients will be assessed to define any clinical improvements. Finally, the investigators will define the characteristics of the patients who will benefit from the rehabilitation provided in the HoSmartAI room. conditions: Neurological Disease conditions: Motor Disorders studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP interventionModelDescription: Longitudinal Pilot study primaryPurpose: HEALTH_SERVICES_RESEARCH masking: NONE count: 80 type: ESTIMATED name: Technological Motor Rehabilitation measure: Key performance indicator (KPI) of the room - Number of treatments measure: Key performance indicator (KPI) ot the room - Number of sessions measure: Room Key performance indicator (KPI) of the room - Number of minutes of therapy measure: Key performance indicator (KPI) of the room - Number of physiotherapists involved measure: Key performance indicator (KPI) of the room - Number of adverse events measure: Box and Blocks Test measure: Reaching Performance Scale measure: Nine Hole Pegboard Test measure: Berg balance scale (BBS) measure: 10 Meter Walk Test (10MWT) measure: Functional Ambulation Categories (FAC) measure: Trunk Control Test (TCT) measure: EuroQol questionnaire (EQ-5D) measure: System Usability Scale (SUS) measure: Short Form Patient Satisfaction Questionnaire (PSQ-18) measure: User Experience Questionnaire (UEQ) measure: Number of falls sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: IRCCS San Camillo Hospital status: RECRUITING city: Venice-Lido state: Venice zip: 30126 country: Italy name: Giorgia Pregnolato role: CONTACT phone: +0412207 phoneExt: 214 email: giorgia.pregnolato@hsancamillo.it lat: 45.4131 lon: 12.3742 hasResults: False
nctId: NCT06270407 id: 270777 id: 2022-001580-28 type: EUDRACT_NUMBER id: 2023-510381-28-00 type: REGISTRY domain: CTIS European Clinical Trial Identification System briefTitle: The Effect of Local Application of Tranexamic Acid Versus Placebo on Postoperative Complications in Plastic Surgery. overallStatus: NOT_YET_RECRUITING date: 2024-05-01 date: 2028-12-31 date: 2029-12-31 date: 2024-02-21 date: 2024-02-21 name: St. Olavs Hospital class: OTHER name: Smerud Medical Research International AS name: Sykehuset Asker og Baerum name: Oslo universitetssykehus HF name: Sykehuset Telemark name: Sykehuset Innlandet HF name: Molde Hospital name: Haukeland University Hospital name: Haraldsplass Deaconess Hospital name: Helse Stavanger HF name: University Hospital of North Norway name: Bodø sykehus name: Helsinki University Central Hospital briefSummary: Study objective:
Participants will receive a single local application of study drug onto their wound surfaces at the end of surgery. Study drug will be identical looking ampoules which contain either TXA or placebo (saline). Neither participants nor study personnel will know the contents of the ampoules. conditions: Surgical Complication studyType: INTERVENTIONAL phases: PHASE4 allocation: NON_RANDOMIZED interventionModel: SINGLE_GROUP interventionModelDescription: Randomized controlled prospective interventional trial primaryPurpose: PREVENTION masking: QUADRUPLE maskingDescription: Identically shaped ampoules containing traneamic acid (Cyklokapron, Pfizer) and 0.9% NaCl (Lavoisier, France) have been identified. The ampoule top part is camouflaged with a tight-fitting black tube which preserves the breaking point on the neck of the ampoule. The ampoules will be re-labeled with study-specific labels (text will be in accordance with Regulation 546/2014, annex VI). Randomized study envelopes will be provided in packages of two, with a 1:1 TXA:Placebo randomization, enabling a within-patient randomization in bilateral procedures.
Randomization, blinding, labelling, shipment of ampoules and keeping of the randomization code will be done by Smerud Medical Research International AS. whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 3000 type: ESTIMATED name: Tranexamic Acid 100 MG/ML name: 0.9%sodium chloride measure: Postoperative re-bleeding measure: Postoperative wound infection measure: Postoperative wound rupture measure: Postoperative thromboembolic events measure: Postoperative seroma measure: Any other postoperative complication sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06270394 id: MJX briefTitle: FAP PET/CT or PET/MR Production in the Diagnosis, Staging, and Efficacy Assessment of Malignant Tumors Application overallStatus: SUSPENDED date: 2022-04-28 date: 2023-07-28 date: 2027-03-31 date: 2024-02-21 date: 2024-02-21 name: The First Affiliated Hospital of Anhui Medical University class: OTHER name: National Natural Science Foundation of China briefSummary: This clinical trial aims to investigate the value of fibroblast activation protein PET/CT(PET/MR) in the diagnosis, staging, and evaluation of treatment outcomes in malignant tumors. The main question it aims to answer is:
The researchers will compare the FDG exams the participants have had to determine the effectiveness of the fibroblast activating protein test. conditions: Malignant Tumors conditions: Positron-Emission Tomography studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: DIAGNOSTIC masking: NONE count: 60 type: ESTIMATED name: 68Ga-Fibroblast activation protein inhibitor measure: 68Ga-Fibroblast Activation Protein Inhibitor-04 Uptake in Gastrointestinal Cancer: Comparison with 18F-FDG measure: Utility of 68Ga-FAPI-04 PET/MRI combines 18F-FDG PET/CT in the postoperative evaluation of gastrointestinal cancers sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT facility: FirstHAnhuiMU city: Hefei state: Anhui zip: 230032 country: China lat: 31.86389 lon: 117.28083 hasResults: False
nctId: NCT06270381 id: UIDB/05299/2020 briefTitle: Empower-Grief: A Study on a Selective Intervention to Prevent Prolonged Grief Disorder overallStatus: RECRUITING date: 2023-08-07 date: 2024-11-01 date: 2024-11-01 date: 2024-02-21 date: 2024-02-21 name: ISPA - Instituto Universitario de Ciencias Psicologicas, Sociais e da Vida class: OTHER briefSummary: The goal of this clinical trial is to test, through a Randomized Controlled Trial (RCT), the efficacy of a selective and short intervention based on second and third-wave cognitive-behavioral interventions (named EMPOWER) for the initial problematic grief reactions and to study potential predictors of adherence and efficacy in bereaved relatives of palliative and oncological patients. The main question is whether EMPOWER intervention is more effective than Treatment as Usual (TAU) in preventing Prolonged Grief Disorder (PGD). Participants with initial indicators of risk of developing PGD will be randomly allocated to EMPOWER and TAU. The primary outcome considered will be symptoms of PGD. The assessment also includes measures of anxiety and depression, attachment, coping, psychological flexibility, posttraumatic growth, and therapeutic alliance. Apart from screening, three assessment moments will be considered: T1: before the first session; T2: at the last session (up to twelve weeks); and T3: follow-up assessment period at 6 months after the previous assessment. conditions: Grief Disorder, Prolonged studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: PREVENTION masking: SINGLE whoMasked: PARTICIPANT count: 44 type: ESTIMATED name: EMPOWER name: Treatment as usual (TAU) measure: Prolonged Grief measure: Anxiety and depression measure: Sociodemographic data measure: Risk Assessment for Grief measure: Coping strategies measure: Adult attachment measure: Psychological inflexibility measure: Social Support measure: Therapeutic alliance measure: Posttraumatic Growth sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Unidade Local de Saúde Santa Maria status: RECRUITING city: Lisboa country: Portugal name: Alexandra Coelho, PhD role: CONTACT phone: 919957534 email: alexandra.moura.coelho@gmail.com lat: 38.71667 lon: -9.13333 hasResults: False
nctId: NCT06270368 id: PREHMO briefTitle: Children Born Preterm: Sustainable Health Monitoring overallStatus: RECRUITING date: 2020-08-05 date: 2025-08-31 date: 2025-12-31 date: 2024-02-21 date: 2024-02-21 name: Meyer Children's Hospital IRCCS class: OTHER name: IRCCS Fondazione Stella Maris briefSummary: Children born preterm are recognized to be at higher risk of short and long term complications and a formal follow-up of infants and children born preterm is recommended by international and national scientific societies. However, in Italy as well as in Tuscany, such a follow up is not usually done, and data are not collected in a structured way. The goal of this observational study is to evaluate the association between a large number of early life exposures and health outcomes and access to care during childhood in infants born preterm. The main questions it aims to answer are: • what is the role of prenatal and perinatal factors in influencing health outcomes during childhood in preterm infants? • What is the role of prenatal and perinatal factors in influencing access to care during childhood? Participants will be asked to attend a follow-up visit for the purpose of collecting health data. conditions: Premature Birth studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 650 type: ESTIMATED measure: Infant development measure: Childhood development measure: Presence of visual or hearing impairement measure: Presence of asthma measure: Access to care sex: ALL minimumAge: 20 Months maximumAge: 66 Months stdAges: CHILD facility: Azienda Ospedaliero-Universitaria Careggi (AOUC) status: RECRUITING city: Firenze country: Italy name: Simone Pratesi role: CONTACT lat: 43.77925 lon: 11.24626 facility: Meyer Children's Hospital IRCCS status: RECRUITING city: Firenze country: Italy name: Vieri Lastrucci role: CONTACT email: vieri.lastrucci@meyer.it lat: 43.77925 lon: 11.24626 facility: Azienda Ospedaliero Universitaria Pisana (AOUP) status: RECRUITING city: Pisa country: Italy name: Rosa Scaramuzzo role: CONTACT lat: 43.70853 lon: 10.4036 facility: Azienda Ospedaliero Universitaria Senese (AOUS) status: RECRUITING city: Siena country: Italy name: Carlo Valerio Bellieni role: CONTACT lat: 43.31822 lon: 11.33064 hasResults: False
nctId: NCT06270355 id: 2023-06555-01 briefTitle: Stockholm Mammography Risk Stratified Trial acronym: SMART overallStatus: NOT_YET_RECRUITING date: 2024-04-08 date: 2028-04-08 date: 2032-04-08 date: 2024-02-21 date: 2024-02-28 name: Karolinska Institutet class: OTHER briefSummary: SMART is a Phase III, randomised, non-blinded screening trial. Women who consent to participate in SMART are randomised to either individualised screening or screening according to the Swedish National Breast Cancer Screening Program. Women randomised to individualised screening get their 2-year risk of breast cancer assessed and women with the highest short-term risk are offered contrast enhanced mammography and a mammogram at 12 months. conditions: Breast Cancer studyType: INTERVENTIONAL phases: PHASE3 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: SCREENING masking: NONE count: 70000 type: ESTIMATED name: Risk based screening measure: Incidence of interval cancers measure: Number of recalled women measure: Number of biopsies measure: Breast cancer measure: Tumor characteristics - Stage measure: Tumor characteristics - Multifocality measure: Tumor characteristics - Receptor status measure: Tumor characteristics - Proliferation measure: Cancer worry measure: Cancer anxiety measure: Side effects related to contrast enhanced mammography measure: Cost-effectiveness measure: Willingness-to-pay sex: FEMALE minimumAge: 40 Years maximumAge: 74 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06270342 id: DTMS briefTitle: The Effect of Dual Task On Upper Extremity Functions In Multiple Sclerosis Patients overallStatus: COMPLETED date: 2023-06-01 date: 2023-09-01 date: 2023-12-15 date: 2024-02-21 date: 2024-02-21 name: Kutahya Health Sciences University class: OTHER briefSummary: The primary aim of this study was to investigate the effect of dual tasking on upper extremity functions in individuals with multiple sclerosis (MS) and compare with healthy controls. Additionally, another aim of our study was to compare the cognitive status, quality of life, fatigue and emotional states of individuals with MS and healthy controls. conditions: Multiple Sclerosis studyType: OBSERVATIONAL observationalModel: CASE_CONTROL timePerspective: OTHER count: 60 type: ACTUAL name: dual task assessment measure: The Minnesota Manual Dexterity Test measure: Dual Task Questionnaire measure: Edinburgh Handedness Questionnaire measure: Expanded Disability Status Scale measure: Brief International Cognitive Assessment Battery for Multiple Sclerosis measure: Beck Depression Scale measure: Fatigue Impact Scale measure: Multiple Sclerosis Quality of Life Questionnaire-54 sex: ALL minimumAge: 18 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Kutahya Health Sciences University city: Kütahya zip: 43100 country: Turkey lat: 39.42417 lon: 29.98333 hasResults: False
nctId: NCT06270329 id: NMTwithKOA briefTitle: Neuromuscular Training Program in Patients With Knee OA (Osteoarthritis) acronym: OA overallStatus: COMPLETED date: 2022-01-15 date: 2023-01-15 date: 2023-06-15 date: 2024-02-21 date: 2024-02-21 name: Kutahya Health Sciences University class: OTHER briefSummary: The aim of this study was to compare the effects of neuromuscular training program and conventional physical therapy program on pain, functional status, physical performance, balance, muscle strength and quality of life in patients with knee osteoarthritis (KOA). conditions: Knee Osteoarthritis studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: randomized controlled clinical trial design primaryPurpose: TREATMENT masking: NONE count: 70 type: ACTUAL name: Neuromuscular training program name: conventional physical therapy program measure: Visual Analog Scale measure: Western Ontario and McMasterUniversities Osteoarhritis Index measure: Time on One Leg Standing measure: Five Times Sit to Stand Test measure: Manual Muscle Test measure: Short Form sex: ALL minimumAge: 40 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Kutahya Health Science University city: Kütahya zip: 43100 country: Turkey lat: 39.42417 lon: 29.98333 hasResults: False
nctId: NCT06270316 id: CT-AMT-191-01 briefTitle: Safety, PK/PD, and Exploratory Efficacy Study of AMT-191 in Classic Fabry Disease overallStatus: NOT_YET_RECRUITING date: 2024-03-15 date: 2027-04-01 date: 2027-04-29 date: 2024-02-21 date: 2024-02-21 name: UniQure Biopharma B.V. class: INDUSTRY briefSummary: This is an open-label multi-center study to evaluate safety and biomarkers of efficacy of a single dose of intravenously-administered AMT-191. The study will also include exploratory functional efficacy assessments. The plan is to investigate 2 sequential dose cohorts in 3-6 Participants per cohort. Participants will be monitored for 24 hours following AMT-191 administration then follow-up study visits will continue for 24 months, during which safety, pharmacokinetics/pharmacodynamics, biomarkers, and efficacy assessments will be performed. Participants will continue receiving their regularly scheduled enzyme replacement therapy (ERT) until they meet the criteria for withdrawal. conditions: Fabry Disease studyType: INTERVENTIONAL phases: PHASE1 phases: PHASE2 allocation: NON_RANDOMIZED interventionModel: SEQUENTIAL primaryPurpose: TREATMENT masking: NONE count: 12 type: ESTIMATED name: AMT-191 measure: Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] measure: Duration of Vector deoxyribonucleic acid (DNA) shedding presented in blood, saliva, feces, semen, and urine sex: MALE minimumAge: 18 Years maximumAge: 50 Years stdAges: ADULT hasResults: False
nctId: NCT06270303 id: 2023-00383-01 briefTitle: Use of a Bone Substitute Material in the Surgical Therapy of Furcation Defects overallStatus: NOT_YET_RECRUITING date: 2024-03-01 date: 2027-03-01 date: 2036-03-01 date: 2024-02-21 date: 2024-02-21 name: Göteborg University class: OTHER name: Johann Wolfgang Goethe University Hospital name: Charite University, Berlin, Germany name: King's College London name: Queen Mary University of London name: Geistlich Pharma AG name: Vastra Gotaland Region briefSummary: The aim of this randomized clinical trial is to evaluate the potential benefit of the use of a bone substitute material in the treatment of furcation degree II-involved molars. The main question it aims to answer is: What is the benefit of the adjunctive use of a bone substitute material in the surgical treatment of furcation degree II-involved molars when compared to open-flap debridement alone?
nctId: NCT06270290 id: 327648 briefTitle: The COSP-RBD Study: Concussions and Contact Sports in RBD vs Controls acronym: COSP-RBD overallStatus: RECRUITING date: 2024-04-22 date: 2025-03-30 date: 2025-03-30 date: 2024-02-21 date: 2024-04-23 name: Guy's and St Thomas' NHS Foundation Trust class: OTHER briefSummary: The goal of this observational study is to investigate concussions and contact sports practices in REM sleep behaviour disorder (RBD).
Researchers will compare an RBD group and a control group (without RBD) to see if the proportion of concussions and exposure to contact sports differ. conditions: REM Sleep Behavior Disorder conditions: Concussion, Brain studyType: OBSERVATIONAL observationalModel: CASE_CONTROL timePerspective: RETROSPECTIVE count: 140 type: ESTIMATED name: Exposure to contact sports or history of concussions measure: Proportion of history of contact sports practice / concussion in RBD and control participants. measure: Differences in concussions characteristics between RBD and control participants. measure: Demographic or clinical differences between RBD participants with and without concussions history. sex: ALL minimumAge: 50 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Guy's & St Thomas' NHS Foundation Trust status: RECRUITING city: London zip: SE1 9RT country: United Kingdom name: Gill Radcliffe role: CONTACT phone: 02071888070 email: gillian.radcliffe@gstt.nhs.uk lat: 51.50853 lon: -0.12574 hasResults: False